Skip to main content
SpringerLink
Log in

Disopyramide

  • Chapter
Cardiovascular Drug Therapy in the Elderly

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 72))

  • 80 Accesses

Abstract

Disopyramide is a class 1A antiarrhythmic agent effective in termination and prevention of many types of ventricular and supraventricular arrhythmias. It is used as second-line therapy after quinidine fails in chronic arrhythmias or for oral continuation of intravenous lidocaine therapy in patients with arrhythmias complicating acute myocardial ischemia. It has been successfully used in all age groups from infants to geriatric patients. The clinical use of disopyramide has been significantly limited due to adverse effects resulting from its anticholinergic properties.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arakawa T, et al: The effect of disopyramide on the His bundle electrogram of normal dog. Jpn Circ J 38:567, 1974.

    Google Scholar 

  2. Befeler B, et al: Electrophysiologic effects of the anti-arrhythmic agent, disopyramide phosphate. Am J Cardiol 35:282, 1975.

    Article  PubMed  CAS  Google Scholar 

  3. Birkhead JS, Vaughan Williams RM: Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods. Br Heart J 39:657, 1977.

    Article  PubMed  CAS  Google Scholar 

  4. Camm J, Spurrell RAJ: An electrophysiological assessment of the effect of intravenous disopyramide in the Wolff-Parkinson-White syndrome.

    Google Scholar 

  5. Danilo P, et al: Effects of disopyramide on electrophysiologic properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 201:701, 1977.

    PubMed  CAS  Google Scholar 

  6. Desai JM, et al: Electrophysiological effects of disopyramide in patients with bundle branch block. Circulation 59:215, 1979.

    PubMed  CAS  Google Scholar 

  7. Wilkinson PR, et al: Electrophysiologic effects of disopyramide in patients with atrioventricular nodal dysfunction. Circulation 66:1211, 1982.

    Article  PubMed  CAS  Google Scholar 

  8. Jennings G, et al: Oral disopyramide in the prophylaxis of arrhythmias following myocardial infarction. Lancet 1:51, 1976.

    Article  PubMed  CAS  Google Scholar 

  9. Rulliere R, et al: Reduction of atrial fibrillation with disopyramide: 70 cases. Nouv Presse Med 5:581, 1976.

    PubMed  CAS  Google Scholar 

  10. Hartel G, et al: Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther 15:551, 1974.

    PubMed  CAS  Google Scholar 

  11. Vismara LA, et al: Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. Am J Cardiol 39:1027, 1977.

    Article  PubMed  CAS  Google Scholar 

  12. Vismara LA, et al: Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug. Clin Pharmacol Ther 16:330, 1974.

    PubMed  CAS  Google Scholar 

  13. Myers JB, et al: Clinical and electrophysiological observations with disopyramide in drug-resistant and recurrent symptomatic arrhythmias. S Afr Med J 54:1083, 1978.

    PubMed  CAS  Google Scholar 

  14. Manz M, et al: Treatment of recurrent sustained ventricular tachycardia with mexiletine and disopyramide. Br Heart J 49:222, 1983.

    Article  PubMed  CAS  Google Scholar 

  15. De Lanerolle TDI: Disopyramide in a case of recurrent ventricular fibrillation. Br Med J 2:975, 1976.

    Article  Google Scholar 

  16. Mayler WG: The pharmacology of disopyramide. J Int Med Res [Suppl 1] 4:8, 1976.

    Google Scholar 

  17. Yu PN: Disopyramide phosphate (Norpace): a new antiarrhythmic drug [editorial]. Circulation 59:236, 1979.

    PubMed  CAS  Google Scholar 

  18. Sutton R: Hemodynamics of intravenous disopyramide. J Int Med Res [Suppl 1] 4:46, 1976.

    PubMed  CAS  Google Scholar 

  19. Befeler B: The hemodynamic effects of disopyramide in patients after open heart surgery. Br Heart J 42:587, 1979.

    Article  Google Scholar 

  20. Kowey P, et al: Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate [abstr]. Circulation [Suppl 3] 62:III-231, 1980.

    Google Scholar 

  21. Gottdiener JS, et al: Effects of disopyramide on left ventricular function: assessment by radionuclide cineangiography [abstr]. Circulation [Suppl 3] 62:III-47, 1980.

    Google Scholar 

  22. Kumana CR, et al: Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction. Br J Clin Pharmacol 14:529, 1982.

    PubMed  CAS  Google Scholar 

  23. Karim A: The pharmacokinetics of Norpace. Angiology [Suppl 1] 26:85, 1975.

    PubMed  CAS  Google Scholar 

  24. Chien JW, et al: Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins. J Pharmacol Sci 63:1877, 1974.

    Article  CAS  Google Scholar 

  25. Cathcart-Rake WF, et al: The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men. Circulation 61:938, 1980.

    PubMed  CAS  Google Scholar 

  26. Bryson SM, et al: Disopyramide serum and pharmacological effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol 6:409, 1978.

    PubMed  CAS  Google Scholar 

  27. Bryson SM, et al: Disopyramide pharmacokinetics during recovery from myocardial infarction. Br J Clin Pharmacol 13:417, 1982.

    PubMed  CAS  Google Scholar 

  28. Hinderling PH, Garrett ER: Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm 4:199, 1976.

    Article  PubMed  CAS  Google Scholar 

  29. Ranney RE, et al: Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent. Arch Int Pharmacodyn Ther 191:162, 1971.

    PubMed  CAS  Google Scholar 

  30. Bonde J, et al: The influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol 20:453, 1985.

    PubMed  CAS  Google Scholar 

  31. Tzivoni D, et al: Disopyramide-induced orsade de pointes. Arch Intern Med 141:946, 1981.

    Article  PubMed  CAS  Google Scholar 

  32. Nicholson WJ, et al: Disopyramide-induced ventricular fibrillation. Am J Cardiol 43:1053, 1979.

    Article  PubMed  CAS  Google Scholar 

  33. Morday F, et al: Disopyramide. Ann Intern Med 93:337, 1982.

    Google Scholar 

  34. Koch-Weser J: Drug therapy: disopyramide. N Engl J Med 300:957, 1979.

    Article  PubMed  CAS  Google Scholar 

  35. Norpace (disopyramide phosphate): an antiarrhythmic drug. Investigational Brochure. Searle Laboratories, 1 May 1977.

    Google Scholar 

  36. Zipes DP Troup PJ: New antiarrhythmic agents. Am J Cardiol 41:1005, 1978.

    Article  PubMed  CAS  Google Scholar 

  37. Teichman SL, et al: Disopyramide-pyridostigmine: report of a beneficial drug interaction. J Cardiovasc Pharmacol 7:108, 1985.

    Article  PubMed  CAS  Google Scholar 

  38. Benditt DC, et al: Recurrent ventricular tachycardia in man: evaluation of disopyramide therapy by intra-cardiac electrical stimulation. Eur J Cardiol 9:255, 1979.

    PubMed  CAS  Google Scholar 

  39. Sbarbaro JA, et al: Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. Am J Cardiol 44:513, 1979.

    Article  PubMed  CAS  Google Scholar 

  40. Deano D, et al: The anti-arrhythmic efficacy of intravenous therapy with disopyramide phosphate. Chest 72:597, 1977.

    Article  Google Scholar 

  41. Podrid PJ, et al: Congestive heart failure caused by oral disopyramide. N Engl J Med 302:614, 1980.

    Article  CAS  Google Scholar 

  42. Bonde J, et al: Disopyramide. Eur J Pharmacol 28:41, 1985.

    Article  CAS  Google Scholar 

  43. Cumming AD, Robertson C: Disopyramide. Br Med J 4:1264, 1979.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Geriatric Cardiology Research Foundation, Tel-Aviv, Israel

    Adam Schneeweiss M.D.

  2. Department of Medicine, University of Heidelberg, Germany

    Gotthard Schettler M.D.

Authors
  1. Adam Schneeweiss M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gotthard Schettler M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Schneeweiss, A., Schettler, G. (1988). Disopyramide. In: Cardiovascular Drug Therapy in the Elderly. Developments in Cardiovascular Medicine, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2063-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2063-0_25

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9225-8

  • Online ISBN: 978-1-4613-2063-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation